Aclarion, Inc., a commercial-stage healthcare technology company, announced that CEO Brent Ness will attend LSI USA 2026, a premier conference for MedTech innovators, investors, and industry leaders. The event, scheduled for March 16-20, 2026 in Dana Point, California, focuses on accelerating medical technology and health technology innovation through in-person meetings.
During the conference, Ness will meet with investors and potential industry partners to discuss Aclarion's progress with Nociscan, the company's proprietary magnetic resonance spectroscopy platform. Nociscan represents a significant advancement in addressing chronic low back pain, a condition affecting millions worldwide. The technology leverages biomarkers and proprietary augmented intelligence algorithms to help physicians distinguish between painful and non-painful discs in patients suffering from chronic low back pain.
The Nociscan platform operates as a software-as-a-service solution that receives magnetic resonance spectroscopy data from MRI machines through a cloud connection. Proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. This biomarker data is then analyzed through proprietary algorithms to indicate whether a disc may be a source of pain. When used alongside other diagnostic tools, Nociscan provides critical insights that help physicians optimize treatment strategies for individual patients.
For more information about Aclarion's technology and corporate developments, readers can visit https://www.aclarion.com. Additional company news is available through their newsroom at https://tinyurl.com/aconnewsroom.
The implications of Aclarion's participation in LSI USA 2026 extend beyond corporate visibility. The conference represents an opportunity to advance medical technology that could transform how chronic low back pain is diagnosed and treated. Current diagnostic methods often struggle to pinpoint exact pain sources, leading to suboptimal treatment outcomes and prolonged patient suffering. Nociscan's evidence-supported approach offers physicians clearer diagnostic information, potentially reducing unnecessary procedures and improving targeted interventions.
For the healthcare industry, successful adoption of technologies like Nociscan could lead to more efficient use of healthcare resources and better patient outcomes. The platform's noninvasive nature and integration with existing MRI infrastructure make it potentially accessible to medical facilities already equipped with standard imaging technology. As chronic low back pain represents one of the most common reasons for healthcare visits worldwide, improved diagnostic tools could have substantial economic and quality-of-life impacts.
Aclarion's focus on combining biomarkers with artificial intelligence reflects broader trends in precision medicine, where diagnostic tools are becoming increasingly sophisticated and personalized. The company's participation in a leading industry conference suggests growing recognition of their technology's potential within the medical community. As healthcare continues to evolve toward more data-driven approaches, platforms like Nociscan may become increasingly important in bridging the gap between diagnostic imaging and clinical decision-making.
